hyperparathyroidism
HYPERPARATHYROIDISM

Hyperparathyroidism is a condition wherein there is an excessive production of parathyroid hormone (PTH).

Primary hyperparathyroidism is the most common endocrine disorder and an important cause of hypercalcemia in ambulatory patients.

Classic signs and symptoms include bone disease, kidney stones and hypercalcinosis.

Primary goal of pharmacological therapy is to normalize calcium levels.

 

Hyperparathyroidism References

  1. AACE/AAES Task Force on Primary Hyperparathyroidism. The American Association of Clinical Endocrinologist and the American Association of Endocrine Surgeons position statement on the diagnosis and management of primary hyperparathyroidism. Endocr Pract. 2005 Jan;11(1):49-54. PMID: 16033736
  2. Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop. J Clin ENdocrinol Metab. 2014 Oct;99(10):3561-3569. doi: 10.1210/jc.2014-1413. Accessed 08 Nov 2017. PMID: 25162665
  3. Bilezikian JP, Cusano NE, Khan AA, Liu JM, Marcocci C, Bandeira F. Primary hyperparathyroidism. May 02, 2016. Nat Rev Dis Primers. 2017 Sep. doi: 10.1038/nrdp.2016.33. PMID: 27194212
  4. Cheng V. Hyperparathyroidism. In: Ferri, F F. Ferri's Clinical Advisor 2018. Philadelphia, PA: Elsevier, Inc; 2018. 655-656. :655-656.e1.
  5. Christakis I A, Perrier N D. Evaluation and management of persistent or recurrent hyperparathyroidism. In: Cameron, J L, Cameron A. Current Surgical Therapy. 12th ed. Philadelphia, PA: Elsevier, Inc; 2017. :792-797.
  6. Darr, E A, Sritharan N, Pellitteri P K, et al. Management of parathyroid disorders. In: Flint P W, Haughey, B H, Lund V, eds. Cummings Otolaryngology. 6th ed. Philadelphia, PA: Elsevier, Inc; 2015. 124, 1929-1956.e8. :124, 1929-1956.e8.
  7. Doyle, D A. Hyperparathyroidism. In: Kleigman R M, Stanton B F, St Geme, J, eds. Nelson Textbook of Pediatrics. 20th ed. Philadelphia, PA: Elsevier, Inc; 2016. Chapter 573, 2694-2697.e1. :Chapter 573, 2694-2697.e1.
  8. Fuleihan G E. Patient education: Primary hyperparathyroidism (Beyond the basics). UpToDate. http://www.uptodate.com/. Aug 2017.
  9. Fuleihan G E, Silverberg S J. Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation. UpToDate. http://www.uptodate.com. Aug 2017.
  10. Gerden E M. Parathyroid carcinoma. Operative Techniques in Otolaryngology (2009): Elsevier, Inc; 2009. :20, 79-81.
  11. Hindié E, Ugur O, Fuster D, et al. 2009 EANM parathyroid guidelines. May 12, 2009. Eur J Nucl Med Mol Imaging. 2009 Jul;36(7):1201-1216. doi: 10.1007/s00259-009-1131-z. Accessed 31 Aug 2017. PMID: 19471928
  12. Maitra, A. The Endocrine System. In: Kumar V, Abbas A K, Aster J C. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Philadelphia, PA: Saunders, an imprint of Elsevier, Inc.; 2015. :1073-1139.
  13. Quinn C E, Udelsman R. The Parathyroid Gland. In: Townsend, C M, Beauchamp, R, Daniel MD, eds. Sabiston Textbook of Surgery. 20th ed. Philadelphia, PA: Elsevier, Inc; 2017. :923-940.
  14. Silverberg S J, Bilezikian J P. Primary Hyperparathyroidism. In: Jameson J L, De Groot, L J, de Kretser, D M, eds. Endocrinology Adult and Pediatric. 7th ed. Philadelphia, PA: Saunders, an imprint of Elsevier, Inc.; 2016. :Chapter 63, 11-5-1124.e6.
  15. Silverberg S J, Fuleihan G E. Primary hyperparathyroidism: Management. UpToDate. http://www.uptodate.com/. Aug 2017.
  16. Taniegra E D. Hyperparathyroidism. American Academy of Family Physician. 2004 2004;69:333-340. http://www.aafp.org/afp.
  17. Wang, T S, Sosa J A. Secondary and tertiary hyperparathyroidism. In: Cameron J L, Cameron A M. Current Surgical Therapy. 12th ed. Philadelphia, PA: Elsevier, Inc; 2017. :798-802.
  18. Wilhelm SM, Wang TS, Ruan DT, et al. The American Association of Endocrine Surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg. 2016 Oct;151(41):959-968. doi: 10.1001/jamasurg.2016.2310. PMID: 27532368
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Nov 2020
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
6 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

3 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.